Drug Discovery
Page 14 to 28 of 60 |   < PREVIOUS PAGE   NEXT PAGE >
Drug Discovery in a Multi-Omics World. Winter 15 By Mike Furness Winter 2015/16
Collectively rare diseases affect millions of people worldwide, but the number of people with any one condition is very small. Finding a cure is difficult as the market is not large enough to justify a big investment in drug development.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part IV: Financial model and analysis. Winter 15 By David M. Kauppi and Dr Stephen Naylor Winter 2015/16
There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) impacts all stakeholders involved in the therapeutic drug sector.

Read More

When two are not enough: lead optimisation beyond matched pairs. Fall 15 By Dr Noel M. O'Boyle, Dr Roger A. Sayle and Dr Matt Segall Fall 2015
Lead optimisation projects progress by making successive enhancements to one or more starting structures. This is a classic multi-objective optimisation procedure where the goal is not only to improve potency but also to improve physicochemical and ADME properties.

Read More

The increasing impact of precision research models on drug discovery and development. Fall 15 Dr Amar Thyagarajan Fall 2015
Animal models are the standard by which we gain insight into the complex biological processes that underlie normal human physiology and disease states. Rodent models such as rats and mice have been used to understand various aspects of human physiology, disease and treatment outcomes.

Read More

How neutron science has enabled innovation in drug design and delivery. Fall 15 By Dr Giovanna Fragneto Fall 2015
Meeting global health challenges, from cancer to viral infections, requires a profound understanding of living processes – not just at the level of cells but right down at the molecular level. And designing the most efficient therapeutics requires an in-depth understanding of the disease.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part III market exclusivity using Intellectual Property and regulatory pathways. Summer 15 By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld Summer 2015
There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) can impact the prescription drug industry for all concerned stakeholders. In part this is due to the fact that the pharmaceutical industry now accrues ~25% of its annual revenues from DRPx products.

Read More

Therapeutic Drug Repurposing: repositioning and rescue. Winter 14 By Dr Stephen Naylor & Judge M. Schonfeld Winter 2014
The pharmaceutical industry is still beleaguered by escalating costs, stagnant productivity and protracted timelines as it struggles to bring therapeutic drugs to market. This situation has been compounded by a ravenous generic drug sector, and patients that have morphed into a discerning consumer population.

Read More

The many roads to cell death: discriminating between apoptosis, necrosis & autophagy. Winter 14 By Dr John Abrams, Dr William G. Telford & Louise Rollins Winter 2014
Cell death is crucial for the proper execution of normal and pathophysiological processes and is ubiquitous in biological systems.

Read More

A novel approach by AstraZeneca to monitor primary DMPK assay performance & understand the inter and intra site assay variability. Fall 14 By Dr Claire Landqvist, Brian Middleton, Dr Barry Jones and Dr Charles O’Donnell Drug Fall 14
An integral part of early drug discovery at AstraZeneca is the process known as the Design Make Test Analyse (DMTA) Cycle. DMTA relies heavily on chemical synthesis and primary screening being delivered within a quick turnaround time.

Read More

Automated patch clamping finally achieves high throughput! Fall 14 By Dr John Comley Fall 14
Two new third-generation automated patch clamp (APC) systems capable of high throughput processing (10,000 data points per eight-hour day) and full robotic integration have been recently launched. The resulting wider choice of primarily 384 APC systems has the potential to intensify competition in the market for APC consumables (patch plates).

Read More

Rules for drug discovery: can simple property criteria help you to find a drug? Spring 14 By Dr Matthew Segall Spring 2014
The years since the publication of Lipinski’s Rule of Five (Ro5)1 in 1997 have seen the growth of a minor industry, dedicated to generating new ‘rules’ for drug discovery. Fuelled by what Kenny and Montanari have termed “Ro5 envy”2, these rules are usually based on simple calculated compound characteristics and define criteria for the selection of compounds in drug discovery. But, can a generic rule be used to reliably select compounds for drug discovery?

Read More

More than genes and cells: drug discovery in the ECM. Winter 13 By Dr William Bains Winter 2013
Drug discovery in the last few decadesMore than genes and cells: drug discovery in the ECM. has focused on the cellular and genetic mechanisms of disease. This has been very successful in cancer, which is a disease of somatic genetics, and moderately successful elsewhere.

Read More

An automated approach to solving Pharma's cardiac toxicity conundrum. Spring 13 By Dr Walter Westerink, Dr Nuria Piñeiro Costas, and Beppy van de Waart Spring 2013
The pharmaceutical industry is facing ever-growing difficulties in developing new drugs and bringing them to market1,2. Many factors stand in the way of R&D productivity, not least of which are shrinking budgets. Yet one of the most pressing challenges continues to be the issue of ensuring that new drug candidates have an acceptable safety profile.

Read More

Pathway Analysis understanding the bridge between environmental cues and cellular response Spring 12 By Dr John Comley Spring 2012
Understanding the function of a protein in the context of normal and abnormal cellular processes requires a comprehensive knowledge not only of its regulation but also of its role in signalling and metabolic networks in the cell. Malfunctioning signalling pathways can lead to a variety of pathologies, hence why they are particularly investigated in the oncology/cancer disease area.

Read More

Drug Discovery
Page 14 to 28 of 60 |   < PREVIOUS PAGE   NEXT PAGE >